Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK.
Department of Medical Oncology, IUCT-Oncopole, Toulouse, France.
Lung Cancer. 2023 Jun;180:107216. doi: 10.1016/j.lungcan.2023.107216. Epub 2023 Apr 24.
Preclinical studies have demonstrated increased efficacy with combined DNA damage response inhibition and immune checkpoint blockade compared with either alone. We assessed olaparib in combination with durvalumab in patients with relapsed small cell lung cancer (SCLC).
Patients with previously treated limited or extensive-stage SCLC received oral olaparib 300 mg twice daily, as run-in for 4 weeks, then with durvalumab (1500 mg intravenously every 4 weeks) until disease progression. Primary endpoints were safety, tolerability, and 12-week disease control rate (DCR). Secondary endpoints included 28-week DCR, objective response rate (ORR), duration of response, progression-free survival, overall survival, change in tumor size, and programmed death-ligand 1 (PD-L1) expression subgroup analyses.
Forty patients were enrolled and analyzed for safety; 38 were analyzed for efficacy. Eleven patients (28.9% [90% confidence interval (CI), 17.2-43.3]) had disease control at 12 weeks. ORR was 10.5% (95% CI, 2.9-24.8). Median progression-free and overall survival were 2.4 (95% CI, 0.9-3.0)months and 7.6(95% CI, 5.6-8.8)months, respectively. The most common adverse events (≥40.0%) were anemia, nausea, and fatigue. Grade ≥ 3 adverse events occurred in 32 patients (80.0%). PD-L1 levels, tumor mutational burden, and other genetic mutations were evaluated, but no significant correlations with clinical outcomes wereobserved.
Tolerability of olaparib with durvalumab was consistent with the safety profile of each agent alone. Although the 12-week DCR did not meet the prespecified target (60%), four patients responded, and median overall survival was promising for a pretreated SCLC population. Further analyses are required to identify patients most likely to benefit from this treatment approach.
临床前研究表明,与单独使用相比,联合 DNA 损伤反应抑制和免疫检查点阻断具有更高的疗效。我们评估了奥拉帕利联合度伐利尤单抗在复发性小细胞肺癌(SCLC)患者中的疗效。
先前接受过治疗的局限期或广泛期 SCLC 患者接受奥拉帕利 300mg 口服,每日 2 次,作为 4 周的导入期,然后使用度伐利尤单抗(静脉注射 1500mg,每 4 周一次),直至疾病进展。主要终点为安全性、耐受性和 12 周疾病控制率(DCR)。次要终点包括 28 周 DCR、客观缓解率(ORR)、缓解持续时间、无进展生存期、总生存期、肿瘤大小变化和程序性死亡配体 1(PD-L1)表达亚组分析。
40 名患者入组并进行了安全性分析;38 名患者进行了疗效分析。11 名患者(28.9%[90%置信区间(CI),17.2-43.3])在 12 周时疾病得到控制。ORR 为 10.5%(95%CI,2.9-24.8)。中位无进展生存期和总生存期分别为 2.4(95%CI,0.9-3.0)个月和 7.6(95%CI,5.6-8.8)个月。最常见的不良反应(≥40.0%)为贫血、恶心和疲劳。32 名患者(80.0%)发生了≥3 级的不良反应。评估了 PD-L1 水平、肿瘤突变负担和其他基因突变,但未观察到与临床结局有显著相关性。
奥拉帕利联合度伐利尤单抗的耐受性与两种药物单独使用的安全性特征一致。尽管 12 周的 DCR 未达到预设目标(60%),但有 4 名患者出现了缓解,并且对于预处理的 SCLC 患者,中位总生存期有希望。需要进一步分析以确定最有可能从这种治疗方法中获益的患者。